The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma. The U.S.

The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma ...

Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% ...

Roberto Mina, MD, discusses the distinguishing factors of the MajesTEC-3 and MajesTEC-9 trials of teclistamab in multiple ...

All-oral therapies provide an attractive treatment option for patients with relapsed/refractory multiple myeloma, given their administration, the convenience of outpatient dosing, and the decreased ...

The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with teclistamab. Teclistamab was approved to treat relapsed/refractory multiple myeloma ...

A Prescription Drug User Fee Act target date of July 10, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application ...

Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...

Wang S, Xu L, Feng J, et al. Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis. Front. Oncol. 2019;9:1513.

Data shows iberdomide combination therapy delivers progression free survival and safety in relapsed and refractory multiple ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...